GH dose 12 months of treatment 24 months of treatment Low Medium High

Slides:

Advertisements

Similar presentations

Remission of Korean Non-Insulin Dependent Diabetes Mellitus by Continuous Subcutaneous Insulin Infusion Treatment Konkuk University Diabetic Center Soobong.

Advertisements

© 2004, Wellsource Inc. Low Carbohydrate Diet and LDL Cholesterol Levels 119 men and women, 24 weeks On the low carb diet, LDL increased slightly On low.

Identify barriers to effective patient teaching. Identify and teach to the standards of medical care for the management of Type 2 diabetes Describe the.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December, 2015.

Table 1 Descriptive Variables __________________________________________________________________________________________ Variables M (SD) Min. Max. n*

NATIONAL CENTER FOR CASE STUDY TEACHING IN SCIENCE Up All Night:

Fightdiabetes.com is a comprehensive website about diabetes. The mission of fightdiabetes.com is to inform, educate, discuss, guide you regarding diabetes.

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Maximum exogenous insulin concentrations were highest for PO insulin (625360 U), followed by DU (453436 U) and SC (10145.7 U) insulin. Peak absorption.

The natural history of Turner syndrome and its associated problems

Adverse Events - Demographics

0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().

Diabetic hypoglycemia from prevention to management.

Insulin Resistance and serum Leptin levels in women with Gestational Diabetes Mellitus GÖKÇE ANIK İLHAN Yasemin Emiroğlu Çekiç1, Gökçe Anık İlhan2, Kadir.

Independent variables (baseline) Loge (HOMA-IR) b P

Estimation of blood glucose in diabetes mellitus

ERT, estrogen replacement therapy

Key publication slides

Figure 2 Top panel shows mean (SE) differences in near-final height (cm) (n = 71) in the AI, GH, and AI/GH groups regardless of length of treatment (n.

The Effect of Retraining on Treatment Success, Quality of Life, and Metabolic Parameters in Patients with Type 1 Diabetes Using an Insulin Pump Med Princ.

Glucose tolerance testing. A

Figure 1. Serum B-ALP levels in normal male (•) and female (○) children as a function of age. Serum B-ALP levels were increased during infancy and puberty.

Without insulin therapy (n = 14)

Insulin resistance in prepubertal children

Prof. Rai Muhammad Asghar Head of Paediatric Department

Young Children with Type 1 Diabetes Mellitus Have Low Rate of Partial Remission Sasigarn A. Bowden, Mary Duck, Robert P Hoffman Division of Endocrinology,

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Fluid retention symptoms Miscellaneous symptoms

Statin Class in Session

Statin Class in Session

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Diagnosis of Acromegaly

GH peak (µg/l) Regression analysis of the GHRH+GHRP-6-elicited GH peaks plotted against body mass index (BMI), in 366 subjects with no endocrine pathology.

(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

#significant difference versus baseline (P<.05).

Effects of 5 yr of GH substitution in 118 GH-deficient adults on serum concentrations of TC, HDL-C, LDL-C and TG as well as on blood glucose, serum insulin.

Bones mass (BMC) and standing height in patients with COGHD compared with normal Russian adults. All values are compared with results obtained.

Endocrine disorders in Thalassaemia

Relationship between karyotype and basal characteristics at GH start

Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Controls r=-0.82; P< GHD r=-0.84; P< Mean IMT (mm)

Control Subjects MPHD Patients Control Subjects MPHD Patients

No GH (n=19) Treated with GH (n=67) Mean (SD) Range Mean (SD) Range

Fig.1 Simple least-squares regression of the relationship between the log of peak GH concentration on standard GH stimulation tests and serum IGF-1 concentrations.

 Height SDS  Weight SDS

 Gruppe A: 0,033mg WH/kg x die  Gruppe B: 0,067mg WH/kg x die

Height velocity (cm/yr) Height velocity (cm/yr)

Comparison between groups

Low-dose hormone therapy and carbohydrate metabolism

CI, confidence interval (95%)

Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15

You and Your Body Growing and Changing S1 Learner Journey

Name that bone....

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Abbildung mod. nach Van Pareren, 2004

Change in LBM (%)‏ LD CD LD CD LD CD

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Glucose, insulin, and AGE levels during an OGC before and after RT

Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

© The Author(s) Published by Science and Education Publishing.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

Effect of treatment on carbohydrate metabolism and skeletal and pubertal maturation GH dose 12 months of treatment 24 months of treatment Low Medium High Low Medium High Fasting plasma glucose (mg/dl) 83±15 81±17 85±11 87±17 86±17 85±16 Fasting insulin (µU/ml) 9±6 13±9 15±11 13±9 13±8 17±10 HbA1c (%) 5.4±0.6 5.3±0.4 5.3±0.5 5.2±0.7 5.2±0.5 5.3±0.4 Mean bone age delay 2.9±1.2 2.5±1.4 2.3±1.5 2.8±1.1 2.7±1.4 2.0±1.0 Bone age advancement (during preceding year) 0.7±0.7 1.2±1.0 1.2±0.9 0.8±0.6 0.7±1.2 1.0±0.8 Patients in puberty (n) 21% (7) 10% (4) 16% (4) 24% (8) 30% (11) 29% (10) Girls in puberty (n) 22% (2) 7% (1) 30% (3) 33% (3) 29% (4) 40% (4) Boys in puberty (n) 20% (5) 13% (3) 4% (1) 20% (5) 30% (7) 25% (6) With the exception of fasting insulin, no significant differences among these parameters were observed as a function of dose, gender or length of treatment Abbildung mod. nach Cohen, 2002